Decentralized trials

The Castor team is thrilled to see an increasing emphasis on diversity of race, gender, and even geography amongst clinical trial participants. Critically, experts call for not just increased diversity on a statistical basis, but that the studied population is representative of the distribution of the disease.

Thought leaders from Castor and Lightship discuss opportunities that will help researchers develop a more successful overall strategy for their patient enrollment.

Download this eBook to gain a comprehensive overview of eConsent, how it satisfies global regulatory requirements and key considerations for ethics board approval.

DTx represent an emerging field of software-driven, evidence-based products intended to “prevent, manage, or treat a medical disease or disorder.” Cybersecurity is a concern for DTx, whether they are being evaluated through clinical research or are aiming at market release.

At Castor, we hope to see DCT extend into all trials as we work alongside researchers in the pursuit of the ultimate goal of democratized clinical research.

Decentralized clinical trials (DCT) are collecting many kinds of data remotely, and this data is only expected to grow in volume. From wireless patches monitoring vitals to an ever-growing list of mobile-connected products, there are new data sources popping up almost everywhere.

eConsent accelerates enrollment, increases retention, and reduces site burden. Find out why it’s the way of the future for clinical trials here.

Download this case study to learn how Castor responded to the disruptive impact of COVID-19 and helped the COVID-RED study implement decentralized clinical trial methods to recruit over 17,825 participants in just 15 weeks.

Castor and Lightship discuss the infrastructure needs for providing the best patient experience and ensuring data integrity in decentralized clinical trials.

eConsent accelerates enrollment, increases retention, and reduces site burden. Learn why it’s the way of the future for clinical trials.